Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Goodwill (2022 - 2024)

Zentalis Pharmaceuticals has reported Goodwill over the past 3 years, most recently at $3.7 million for Q3 2024.

  • Quarterly results put Goodwill at $3.7 million for Q3 2024, changed 0.0% from a year ago — trailing twelve months through Sep 2024 was $3.7 million (changed 0.0% YoY), and the annual figure for FY2023 was $3.7 million, changed 0.0%.
  • Goodwill for Q3 2024 was $3.7 million at Zentalis Pharmaceuticals, roughly flat from $3.7 million in the prior quarter.
  • Over the last five years, Goodwill for ZNTL hit a ceiling of $3.7 million in Q1 2022 and a floor of $3.7 million in Q1 2022.
  • Median Goodwill over the past 3 years was $3.7 million (2022), compared with a mean of $3.7 million.
  • Peak annual rise in Goodwill hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Zentalis Pharmaceuticals' Goodwill stood at $3.7 million in 2022, then changed by 0.0% to $3.7 million in 2023, then changed by 0.0% to $3.7 million in 2024.
  • The last three reported values for Goodwill were $3.7 million (Q3 2024), $3.7 million (Q2 2024), and $3.7 million (Q1 2024) per Business Quant data.